Beginning with ustekinumab (FDA approved in 2009), monoclonal antibodies against IL-23 (specifically, the pro-inflammatory p19 subunit, IL-23p19) have become a mainstay of treatment for psoriasis and inflammatory bowel disease. This evidence concerns the gene IL37 and psoriasis.